Evidence map›Paper›PMID 27740596›Full record

ArticleBiology2016

Development of a qPCR Method to Measure Mitochondrial and Genomic DNA Damage with Application to Chemotherapy-Induced DNA Damage and Cryopreserved Cells.

Stephen O Evans, Michael B Jameson, Ray T M Cursons, Linda M Peters, Steve Bird, Gregory M Jacobson

Abstract read
In one paragraph

Article in Biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Stephen O EvansBiomedical Research Unit, School of Science, University of Waikato Private Bag 3105, Hamilton 3240, New Zealand. soe2@students.waikato.ac.nz.
Michael B JamesonDepartment of Oncology, Regional Cancer Centre, Waikato Hospital, Hamilton West 3204, New Zealand. Michael.Jameson@waikatodhb.health.nz.
Ray T M CursonsBiomedical Research Unit, School of Science, University of Waikato Private Bag 3105, Hamilton 3240, New Zealand. rtmc@waikato.ac.nz.
Linda M PetersBiomedical Research Unit, School of Science, University of Waikato Private Bag 3105, Hamilton 3240, New Zealand. lpeters@waikato.ac.nz.
Steve BirdBiomedical Research Unit, School of Science, University of Waikato Private Bag 3105, Hamilton 3240, New Zealand. sbird@waikato.ac.nz.
Gregory M JacobsonBiomedical Research Unit, School of Science, University of Waikato Private Bag 3105, Hamilton 3240, New Zealand. gmjacobson@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

DNA damage quantitation assays such as the comet assay have focused on the measurement of total nuclear damage per cell. The adoption of PCR-based techniques to quantify DNA damage has enabled sequence- and organelle-specific assessment of DNA lesions. Here we report on an adaptation of a qPCR technique to assess DNA damage in nuclear and mitochondrial targets relative to control. Novel aspects of this assay include application of the assay to the Rotor-Gene platform with optimized DNA polymerase/fluorophore/primer set combination in a touchdown PCR protocol. Assay validation was performed using ultraviolet C radiation in A549 and THP1 cancer cell lines. A comparison was made to the comet assay applied to peripheral blood mononuclear cells, and an estimation of the effects of cryopreservation on ultraviolet C-induced DNA damage was carried out. Finally, dose responses for DNA damage were measured in peripheral blood mononuclear cells following exposure to the cytotoxic agents bleomycin and cisplatin. We show reproducible experimental outputs across the tested conditions and concordance with published findings with respect to mitochondrial and nuclear genotoxic susceptibilities. The application of this DNA damage assay to a wide range of clinical and laboratory-derived samples is both feasible and resource-efficient.

Indexed as

A549bleomycincisplatincomet assayDNA damageLORD-QPBMCqPCRTHP1

Identifiers

PMID27740596
PMCPMC5192419

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.